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The incidence of lung cancer among individuals infected with the human immunodeﬁciency virus (HIV) is elevated compared
to that among the general population. This study examines the prevalence of HIV and its impact on outcomes among Medicare
beneﬁciaries who are 65 years of age or older and were diagnosed with nonsmall cell lung cancer (NSCLC) between 1997 and 2008.
Prevalence of HIV was estimated using the Poisson point estimate and its 95% conﬁdence interval. Relative risks for potential
risk factors were estimated using the log-binomial model. A total of 111,219 Medicare beneﬁciaries met the study criteria. The
prevalence of HIV was 156.4 per 100,000 (95% CI: 140.8 to 173.8) and has increased with time. Stage at NSCLC diagnosis did
not vary by HIV status. Mortality rates due to all causes were 44%, 76%, and 88% for patients with stage I/II, III, and IV NSCLC,
respectively. Across stages of disease, there was no diﬀerence between those who were HIV-infected and those who were not
with respect to overall mortality. HIV patients, however, were more likely to die of causes other than lung cancer than their
immunocompetent counterparts.
1.Introduction
With the widespread use of highly active antiretroviral
therapy (HAART), the incidence of non-AIDS deﬁning
malignancies among HIV-infected persons has increased
[1, 2]. The most frequently reported non-AIDS deﬁning
cancer among HIV-infected individuals is lung cancer. The
incidence of lung cancer among individuals infected with
human immunodeﬁciency virus (HIV) is elevated compared
to the incidence in the general population [1–8] and has
increased with time [2]. HIV-infected individuals are at
least twice as likely as those who are not infected with
HIV to be diagnosed with lung cancer [1, 6, 8]. The risk
of lung cancer among HIV-infected patients is inversely
related to CD4 count, a measure of immune function [9],
and it has been suggested that use of antiretroviral viral
therapy may reduce the risk of lung cancer [10]. At the
time of lung cancer diagnosis, HIV-infected patients were
younger than those who were not shown to have HIV
[11, 12].
Survival of HIV-infected lung cancer patients was similar
to that of their immunocompetent counterparts when the
majority of HIV-infected patients were on HAART [11, 13].
Positive prognostic factors for survival among HIV-infected
lungcancercasesaretheuseofHAART[14]andCD4counts
[15]. The impact of HIV infection on the population of
lung cancer patients is unclear. This study uses data from
the SEER-Medicare database to determine the prevalence of
HIV infection among Medicare beneﬁciaries with nonsmall
cell lung cancer (NSCLC) and its implications for their
outcomes.
2.MaterialsandMethods
The basis for this study was the SEER-Medicare database
which links Medicare claims data with patients iden-
tiﬁed through cancer registries as part of the Surveil-
lance Epidemiology and End Results (SEERs) program
(http://www.seer.cancer.gov/). The SEER database includes2 Journal of Cancer Epidemiology
information on patient demographic characteristics, pri-
mary tumor site, histology and stage of disease at diagnosis,
initial course of treatment, and follow-up vital status from
population-based registries in the USA.
This study includes patients who were diagnosed with
nonsmall cell lung cancer between 1998 and 2007 as their
ﬁrst cancer, were not diagnosed at autopsy or by death cer-
tiﬁcate, were staged using the American Joint Commission
on Cancer (AJCC) staging system [16], were covered by
MedicarePartsAandBcontinuouslyfor6monthspreceding
lung cancer diagnosis and 2 months after diagnosis, qualiﬁed
for Medicare based on age, and were 65 years of age or older
atthetimeofthelungcancerdiagnosis.MedicarePartsAand
B cover hospitalization and outpatient services, respectively.
Patients who qualiﬁed for Medicare based on disability, end-
stage renal disease alone, or for whom the basis of Medicare
qualiﬁcation was unknown were excluded from all analyses.
A total of 111,219 Medicare beneﬁciaries met these criteria.
HIV patients were identiﬁed based on the International
ClassiﬁcationofDiseases,version9,“042”diagnosisreported
in the databases of Medicare claims for health care services
givenbetween1998and2009.TheMedicareclaimsdatabases
were Medicare Provider Analysis and Review (MEDPAR),
Carrier Claims (NCH), Outpatient Claims (OUTPT), and
Home Health Agency (HHA). Prevalent cases of HIV were
deﬁned as cases whose ﬁrst Medicare claim with an HIV
diagnosis either preceded the diagnosis of lung cancer or
occurred within 90 days after lung cancer diagnosis.
Age at diagnosis was categorized in 5-year intervals (65–
69, 70–74, 75–84, 85+). For purposes of this study, they
were further grouped into 3 age groups: 65–74, 75–84,
and 85 years of age and older. The areas of residence for
patients were classiﬁed as Big Metro (residing in counties
with populations in excess of 1 million), Metro (residing in
counties with populations between 250,000 and 1 million),
or Other (residing in counties with populations below
250,000).
Prevalence of HIV was estimated assuming its point
estimate and 95% Poisson conﬁdence intervals. Relative risks
(RR) and their 95% conﬁdence intervals were estimated
using the log-binomial regression model [17]. Pearson’s chi-
square test and Fisher’s exact test were used to compare
HIV and non-HIV lung cancer patients with respect to
demographic characteristics. The Cochran-Armitage trend
test was used to evaluate trends in prevalence of HIV
over time. The Cochran-Mantel-Haenszel test was used to
compare HIV and non-HIV groups with respect to the
mortality rates across stages of disease. The log-binomial
regression model [17] was used to evaluate the association
between mortality due to all causes and lung cancer with
demographic factors, stage of disease and HIV status, and
their relative risks.
3. Results
A total of 174 NSCLC cases had an HIV diagnosis. The
demographic proﬁle among HIV patients diﬀered from that
of their HIV negative counterparts (Table 1). NSCLC pa-
tients infected with HIV were more likely to be men, from a
Table 1: Demographic characteristics of NSCLC cases based on
HIV infection status.
HIV (N = 174) Non-HIV
(N = 111,045)
Men (%) 67.8 52.4
P<0.001∗
Age, years (%)
65–74 60.9 50.0
75–84 35.6 41.9
85+ 3.5 8.1
P = 0.005∗
Race (%)
White 58.6 86.7
Black 34.2 7.9
Other 7.2 5.4
P<0.001∗
Never married (%)
Men 33.1 7.5
P<0.001∗
Women 5.4 6.6
P = 0.717∗
Both 24.1 7.0
P<0.001∗
Urban/Rural (%)
Big Metro 81.6 61.2
Metro 17.2 25.9
Other 1.2 12.9
P<0.001∗
Stage of disease
I 30.5 26.3
II 2.3 2.8
III 31.6 31.8
IV 35.6 39.1
P = 0.064∗
Histology
Large cell carcinoma 5.8 4.4
Squamous cell
carcinoma 24.1 25.4
Adenocarcinoma 35.1 35.4
Other, unspeciﬁed 35.1 34.8
P = 0.847∗
∗For comparing HIV and non-HIV patients.
minority group, not currently or previously married, res-
idents of a large metropolitan area, and younger than
their non-HIV counterparts. Among HIV-infected NSCLC
patients, over 40% were from a minority population in com-
parisonto13%ofthosewhowerenotHIV-infected.Individ-
uals who were 75 years or older at diagnosis comprised half
of the non-HIV and only 39% of the HIV-infected NSCLC
patients. There were no signiﬁcant diﬀerences between
HIV and non-HIV patients with respect to stage of diseaseJournal of Cancer Epidemiology 3
Table 2: Prevalence of HIV among Medicare Beneﬁciaries 65 years of age and older who qualiﬁed based on age.
Non-HIV (N)H I V ( N) Prevalence per 100,000
(95% CI) Relative risk (95% CI) P value
Gender
Male 58,211 118 202.3 (168.9, 242.3) 1.91 (1.39, 2.63) <0.001
Female 52,834 56 105.9 (81.5, 137.6) Reference
Race
White 96,437 102 105.7 (87.0, 128.3) Reference
Black 8,771 64 724.4 (567.0, 925.5) 6.86 (5.02, 9.36) <0.001
Other 5,837 8 136.9 (68.4, 273.7) 1.30 (0.63, 2.66) 0.480
Age, years
65–74 55,491 106 190.7 (157.6, 230.6) Reference
75–84 46,585 62 132.9 (103.6, 170.5) 0.70 (0.51, 0.95) 0.024
85+ 8,969 6 66.9 (30.0, 148.8) 0.35 (0.15, 0.80) 0.012
Marital status—Men
Never married 4,346 39 889.4 (649.8, 1217.3) 6.07 (4.14, 8.90) <0.001
Other 53,865 79 146.4 (117.5, 182.6) Reference
Marital status—Women
Never married 3,465 3 86.5 (27.9, 268.2) 0.81 (0.25, 2.58) 0.717
Other 49,369 53 107.2 (81.9, 140.4) Reference
Urban/Rural Residence
Big Metro 67,937 142 208.6 (176.9, 245.9) Reference
Metro 28,725 30 104.3 (72.9, 149.2) 0.50 (0.34, 0.74) <0.001
Other 14,383 2 13.9 (3.5, 55.6) 0.07 (0.02, 0.27) <0.001
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Figure 1: Prevalence of HIV over time among Medicare beneﬁ-
ciaries diagnosed with nonsmall cell lung cancer from the SEER-
Medicare database.
(P = 0.604) or histologic type (P = 0.847) at the time of
NSCLC diagnosis.
The prevalence of HIV was 156.4 per 100,000 (95%
CI: 140.8 to 173.8) among Medicare beneﬁciaries. Men
were almost twice as likely to be HIV-infected than women
(Table 2) and African-Americans were 6.9 times as likely
to be HIV-infected than white beneﬁciaries. Prevalence of
HIV declined with age. Men who had never been married
were 6 times more likely to have HIV than their currently
or previously married counterparts. For women, remaining
single was not associated with an increased risk of HIV. From
1998 to 2007, the prevalence of HIV tripled from 69.1 to
216.6 per 100,000 (P<0.001) (Figure 1).
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Figure 2: Mortality rate by stage of disease, HIV status, and cause
from the SEER-Medicare database.
Mortality rates due to all causes were 44%, 76%, and
88% for patients with stages I/II, III, and IV NSCLC,
respectively, and did not vary with HIV status (P = 0.320)
(Figure 2). HIV-infected patients were less likely to die of
lung cancer than those who were not infected with HIV
(P = 0.004). Death due to HIV was reported for 2.9%
HIV-infected patients and none of non-HIV patients. In4 Journal of Cancer Epidemiology
Table 3: Relative Risk (RR) for all causes mortality and lung cancer mortality.
Mortality due to any cause Mortality due to lung cancer
Relative risk (95% CI) P value Relative risk (95% CI) P value
Stage III versus I/II 1.66 (1.64, 1.68) <0.001 2.11 (2.08, 2.15) <0.001
Stage IV versus I/II 1.80 (1.78, 1.82) <0.001 2.40 (2.36, 2.44) <0.001
Male versus female 1.05 (1.04, 1.05) <0.001 1.05 (1.04, 1.06) <0.001
Black versus white 1.02 (1.01, 1.03) <0.001 0.99 (0.98, 1.01) 0.472
Other versus white 0.96 (0.94, 0.97) <0.001 0.94 (0.92, 0.96) <0.001
Age 75–84 versus 65–74 1.04 (1.03, 1.05) <0.001 1.02 (1.01, 1.03) <0.001
Age 85+ versus 65–74 1.07 (1.06, 1.08) <0.001 1.02 (1.01, 1.03) 0.008
Metro versus Big Metro 1.00 (1.00, 1.01) 0.569 1.00 (0.99, 1.01) 0.458
Other versus Big Metro 1.01 (1.00, 1.02) 0.066 1.01 (1.00, 1.02) 0.088
Single versus Other 1.00 (0.99, 1.01) 0.079 0.99 (0.97, 1.01) 0.076
HIV versus non-HIV 0.94 (0.86, 1.02) 0.132 0.84 (0.73, 0.96) 0.011
a multivariate analysis, stage of disease, gender, age, and race
were associated with mortality due to all causes and due to
lung cancer (Table 3). HIV infection was not signiﬁcantly
associated with mortality due to all causes but was negatively
associated with lung cancer mortality.
4. Discussion
In comparison to HIV-infected Medicare beneﬁciaries with-
out cancer, the HIV-infected lung cancer cases in our
study were older, but similar with respect to gender and
racial distributions [18]. The larger proportion of men
and minorities among the HIV-infected lung cancer cases
reﬂects the population characteristics of HIV infection in
the USA [19]. The ﬁnding that African-Americans and men
are overrepresented in the HIV positive lung cancer cases
can be attributed to their higher prevalence of HIV in the
population overall [19] and the higher incidence of lung
cancer for African-American men as compared to white
men [20]. One-third of the HIV-infected men had never
been married, 4 times the proportion among the non-
HIV Medicare beneﬁciaries, which suggests that a sizable
proportion of the HIV-infected Medicare lung cancer cases
may be among men who have sex with men (MSM).
The overall prevalence of HIV among elderly Medicare
beneﬁciaries diagnosed with NSCLC of 156.4 per 100,000 is
1.6 times greater than the rate of persons living with HIV
among those 65 years of age or older in the USA in 2008
[21]. Higher prevalence rates for documented HIV infection
among persons 65 years of age and older were reported in a
studyof Veterans Aﬀairs health systems [22]. HIV prevalence
rates in this study are higher than those reported among
elderly Medicare beneﬁciaries by Gilden et al. [18]; however,
that study used a more stringent criteria for deﬁning HIV
patients [18]. The disparity in HIV prevalence based on race
and gender among the Medicare NSCLC patients was similar
to that in the general population where blacks are 8 times
more likely to be infected with HIV than whites, and men
were 3 times more likely than women to be HIV-infected
[21].
The prevalence of HIV among men with NSCLC who
were currently or previously married is slightly lower than
the reported prevalence of HIV among adult men under 60
years of age who are not MSM [23, 24]. In this study, single
men who had never married were 6 times more likely to have
HIV than those who had been married. Younger MSM are
36 times more likely to be HIV-infected than other men [23].
The smaller disparity in this study may be due to the older
age of the NSCLC cases and the possibility that a proportion
of men who had never married are not MSM. The ﬁnding
that the prevalence of HIV was higher for NSCLC patients
that resided in large metropolitan areas is consistent with
the urban-rural distribution of HIV in the USA. The rate of
persons living with a diagnosis of HIV infection is twice as
high in metropolitan areas of 500,000 residents or more than
in smaller areas [25].
The younger age at lung cancer diagnosis for the HIV
patients has been previously reported [11, 12]. It is not
known whether this represents earlier exposure to known
risk factors such as smoking and tobacco use or the
independent eﬀect of HIV infection [26, 27]. In comparison
to the general population where 23.5% of men and 17.9%
of women report that they are current cigarette smokers
[26, 28], it has been reported that over 40% of HIV-
infected individuals are cigarette smokers [29, 30]. The
higherrateofsmoking hasbeenlinkedtoanincreasedriskof
morbidity for HIV-infected persons from non-AIDS-related
cancers (including lung cancer), cardiovascular disease, and
pneumonia [29].
The ﬁnding that stage of lung cancer at the time of
diagnosis did not diﬀer between HIV and non-HIV infected
beneﬁciaries is correlated with reports that the elevated risk
of lung cancer for HIV-infected individuals does not vary
by stage of disease [12]. Since 94% of those 65 years of
age or older have Medicare coverage [31], the comparable
distribution of stages may reﬂect the fact that, in this age
group, HIV-infected patients have access to health care
similar to that of immunocompetent patients.
The increasing prevalence of HIV over time among
elderly Medicare beneﬁciaries with lung cancer reﬂectsJournal of Cancer Epidemiology 5
the temporal increase in rate of persons living with HIV
[32]. Recently, the prevalence of HIV among those 65 years
of age or older has risen from 51.1 per 100,000 in 2005
[32] to 99.0 per 100,000 in 2008 [21]. Since the overall HIV
incidence has not increased [33, 34], much of the increase in
HIV prevalence may be attributed to eﬀect of highly active
antiretroviral therapy in extending survival which places
some HIV patients at risk for chronic diseases of the aging.
The ﬁnding that HIV infection did not have an impact
on overall survival of lung cancer patients conﬁrms other
reports [11, 13] and suggests that HIV and lung cancer serve
as competing risks for this population. The lower mortality
due to lung cancer among HIV patients can be attributed to
their mortality due to HIV-related causes.
Thereareanumberoflimitationstothisstudy.Theissues
related to generalization from the SEER population to the
US population as a whole have been previously described
[35]. In comparison to the US population as a whole, the
SEERpopulationismoreaﬄuent,morehighlyeducated,and
more urban [35]. The SEER-Medicare-linked database does
not contain information on risk factors for lung cancer such
as tobacco use or occupational exposure, nor does it provide
measures of severity of HIV infection such as HIV load or
CD4 counts. Similarly, the mechanism of HIV acquisition
is not captured as part of the database. Identiﬁcation of
the HIV cases was based on diagnostic codes provided on
Medicare claims data, not HIV serology. Marital status was
used as an indicator of sexual orientation among men since
this information was not collected in the database.
5. Conclusion
ThispaperdemonstratesthattheprevalenceofHIVinfection
among NSCLC patients over 65 years of age is growing
with time. The risk factors associated with HIV infection in
olderNSCLCpatientsreﬂectthoseinthegeneralpopulation.
HIV infection is not associated with an increase in overall
mortality among NSCLC patients but serves as a competing
risk with lung cancer so that HIV-infected individuals have a
lower mortality due to lung cancer.
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